# OnCo record nct05797168 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05797168/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05797168", "NCT05797168" ;
  schema:name "Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors"@en ;
  schema:alternateName "FONTANA"@en ;
  schema:description "A phase 1/2 trial of AZD5335, Saruparib, Bevacizumab in ovarian cancer and endometrial cancer, run by AstraZeneca, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05797168/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05797168> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-06-05" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/endometrial/> ;
  onco:drugs <https://onco.cc/drugs/azd5335/>, <https://onco.cc/drugs/saruparib/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/palacaparib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .